Mibefradil

A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.

Also Known As:

Mibefradil Dihydrochloride; Posicor; Ro 40-5967; Ro 40 5967; Ro 405967; (1S,2S)-(2-((3-(2-benzimidazolyl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate

Networked: 235 relevant articles (32 outcomes, 75 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kawabata, Atsufumi: 4 articles (10/2012 - 11/2007)
2.	Sekiguchi, Fumiko: 4 articles (10/2012 - 11/2007)
3.	Cantí, Carles: 3 articles (05/2022 - 01/2018)
4.	Herreros, Judit: 3 articles (05/2022 - 01/2018)
5.	Visa, Anna: 3 articles (05/2022 - 01/2018)
6.	Nishikawa, Hiroyuki: 3 articles (10/2012 - 11/2007)
7.	Kawabata, A: 3 articles (08/2011 - 06/2009)
8.	Matsunami, M: 3 articles (08/2011 - 06/2009)
9.	Unger, T: 3 articles (01/2001 - 01/2000)
10.	Alza, Lía: 2 articles (05/2022 - 01/2019)

Related Diseases

1.	Hypertension (High Blood Pressure) 04/01/1998 - "Mibefradil, at the recommended doses of 50 to 100 mg/day, is safe and effective for the treatment of mild-to-moderate hypertension." 12/01/1997 - "These studies established that at doses of 50 and 100 mg, mibefradil is an effective, well tolerated and safe treatment for high blood pressure. " 09/01/1998 - "In a study of the effect of hypertension on mibefradil pharmacokinetics, 12 patients received oral mibefradil once daily at doses of 50, 100, 150, or 200 mg in 100 mL orange juice for 8 days. " 05/01/1998 - "In clinical studies of hypertension, mibefradil 50 and 100 mg/day reduced trough sitting diastolic and systolic blood pressures in a dose-related manner. " 11/01/1997 - "Mibefradil Hypertension Study Group."
2.	Heart Failure 11/06/1997 - "The apparent lack of negative inotropic activity and neurohormonal activity with mibefradil, as well as its favorable effects on cardiac remodeling in experimental models, suggest that this agent may be beneficial in congestive heart failure. " 09/01/1999 - "In humans, however, major metabolic drug interactions independent of T-type Ca2+ channel blockade made it impossible to determine the efficacy of mibefradil in treating heart failure; indeed, these interactions led to the withdrawal of the drug from the market." 03/31/2000 - "), ejection fraction 0.21+/-0.07) treated with mibefradil or placebo, who participated in the MACH-I (Mortality Assessment in Chronic Heart failure) trial in our center, and compared them with 18 healthy matched controls. " 01/01/2000 - "The prototype drug, mibefradil, was rigorously tested for use in heart failure in the Mortality Assessment in Congestive Heart Failure (MACH-1) trial. " 10/01/1999 - "The drug was finally withdrawn after a study in patients with congestive heart failure showed a trend to higher mortality with mibefradil. "
3.	Stable Angina 04/15/1997 - "This study assessed the safety, tolerability, and efficacy of mibefradil when added to beta-blocker monotherapy in patients with chronic stable angina pectoris. " 04/15/1997 - "Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris." 08/21/1997 - "Taken together, these studies indicate that mibefradil is an effective and well-tolerated once-daily treatment for chronic stable angina pectoris at doses of 50 and 100 mg, which are the lowest and highest effective doses of the compound, respectively." 06/01/1998 - "The efficacy and safety of mibefradil in subgroups of patients with chronic stable angina pectoris." 08/21/1997 - "Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris."
4.	Fibrosis (Cirrhosis) 01/01/1998 - "Mibefradil was also associated with improvements in cardiac hemodynamics, a reduction in LV weight and fibrosis. " 02/01/2000 - "Chronic treatment with mibefradil reduced interstitial and perivascular fibrosis and improved cardiac function in MI-induced heart failure in rats. " 02/01/1997 - "Mibefradil in a rat model improved survival to the same extent as an ACE inhibitor, without impairing LV function, and was associated with a reduction in LV weight and fibrosis. " 09/01/2004 - "These markers of fibrosis were attenuated by treatment with either amlodipine or mibefradil. " 01/01/2001 - "In contrast to amlodipine treatment, before and after MI started mibefradil and verapamil treatment decreased HR. Pretreatment with all CCA reduced IS and increased ST, whereas only mibefradil and amlodipine pretreatment prevented LVD and cardiac fibrosis. "
5.	Angina Pectoris 02/01/1998 - "Treatment of chronic angina pectoris with combination mibefradil and beta-blocker therapy." 12/01/1997 - "Mibefradil is a new Ca2+ antagonist that is effective in hypertension and angina pectoris. " 12/01/1997 - "MIBEFRADIL IN THE TREATMENT OF ANGINA PECTORIS: The efficacy, safety, and tolerability of 50 and 100 mg mibefradil in the treatment of chronic stable angina pectoris was tested in six randomized parallel-design studies. " 01/01/1997 - "The first of this new class, mibefradil, is characterized by selective blockade of T-type calcium-ion channels and has been shown in a few studies to reduce the frequency and duration of asymptomatic ischemic episodes in patients with stable exertional angina pectoris. " 11/01/1991 - "We screened the antiischemic, hemodynamic, and inotropic effects of different dosages of the new calcium channel blocker Ro 40-5967 in 65 patients with stable effort-induced angina pectoris. "

Related Drugs and Biologics

1.	Calcium
2.	Antihypertensive Agents (Antihypertensives)
3.	Nifedipine (Adalat)
4.	Amlodipine (Norvasc)
5.	Verapamil (Calan)
6.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
7.	Diltiazem (Cardizem)
8.	T-Type Calcium Channels (T-Type Calcium Channel)
9.	Calcium Channel Blockers (Blockers, Calcium Channel)
10.	Nitrates

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation
3.	Drug Therapy (Chemotherapy)
4.	Medication Errors (Medication Error)
5.	Intraventricular Injections